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Telomerase activity in gestational trophoblastic
disease
A N Y Cheung, D K Zhang, Y Liu, H Y S Ngan, D H Shen, S W Tsao
Abstract
Aims-To investigate the pattern oftelom-
erase activity in hydatidiform mole as
compared with normal placenta and cho-
riocarcinoma, and to determine the prog-
nostic significance of telomerase activity
in hydatidiform mole.
Methods-Telomerase activity in 35 cases
of hydatidiform mole, 35 normal placen-
tas, one choriocarcinoma sample, and two
choriocarcinoma cell lines (JAR, JEG3)
was determined using the sensitive
polymerase chain reaction based telom-
eric repeat amplification protocol (TRAP)
assay. Two cases of breast carcinoma and
two cases of ovarian carcinoma were also
included as positive controls in the telom-
erase assay.
Results-Telomerase activity was detected
in 11 of 30 early placentas (36.7%), one of
five term placentas (20%), five of 27
hydatidiform moles which regressed spon-
taneously (18.5%), and six of eight hyda-
tidiform moles which developed persistent
trophoblastic disease (75%) (including
three which developed metastases). Hyda-
tidiform moles which subsequently devel-
oped persistent disease, especially those
which metastasised, were more likely to
express telomerase activity (p < 0.01).
However, there was no significant differ-
ence in the frequency oftelomerase activity
between early placentas and hydatidiform
mole. Strong telomerase activity was ob-
served in choriocarcinoma tissue, chorio-
carcinoma cell lines, and ovarian and
breast carcinomas.
Conclusions-Telomerase activation oc-
curs in hydatidiform mole with a similar
incidence to early normal placentas. This
supports the concept that hydatidiform
mole is essentially an abnormal concep-
tus. There is an association between
telomerase activation and the develop-
ment of persistent trophoblastic disease.
Further study is warrant to confirm the
prognostic significance of telomerase ac-
tivity in hydatidiform mole.
(7 Clin Pathol 1999;52:588-592)
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Repetitive telomere sequences are present at
the ends of eukaryotic chromosomes which
protect the ends from damage and rearrange-
ments. Progressive shortening of telomeric
sequences is associated with cell division owing
to the end replication problem involved in
DNA replication. Telomerase is a special type
of reverse transcriptase which stabilises the
telomeric ends of human chromosomes by
adding the TTAGGG repeats onto the chro-
mosome ends. Most normal somatic cells lack
telomerase activity, and successive cell division
will result in progressive shortening of telom-
eres leading to chromosomal instability. Telo-
mere shortening, both in vivo and in vitro, has
been postulated to be the mitotic clock count-
ing the number of mitoses that the cells have
undertaken. Excessive shortening of telomeric
length may trigger the onset of cell senescence.
The telomeres of tumour cells have to be
maintained in order to sustain their continuous
proliferative capacities, and telomerase is com-
monly activated in human tumours for this
purpose.' 2
The placenta is a dynamic organ with
programmed proliferation and differentiation
of trophoblasts whose proper function is
important for maintaining a successful preg-
nancy. Abnormal proliferation of trophoblasts
may result in gestational trophoblastic disease
which encompasses a heterogeneous group of
lesions including hydatidiform mole, chorio-
carcinoma, and placental site trophoblastic
tumour.3 These lesions are unique, since they
can be considered as allografts arising from a
conceptus that invades the maternal tissues.
Significant differences in morphology and
clinical behaviour have been documented in
these closely related entities. Some of these
lesions, such as choriocarcinoma and placental
site trophoblastic tumour, are definitely neo-
plastic, while hydatidiform moles may just be
abnormal placentas that are prone to malignant
transformation. Hydatidiform mole is diag-
nosed histologically by the presence of hy-
dropic swelling of the chorionic villi and prolif-
eration of the trophoblasts. It is associated with
a substantial risk (10-15%) of developing per-
sistent gestational trophoblastic disease and
may even develop into choriocarcinoma even-
tually. The mechanisms involved in the patho-
genesis and progression of hydatidiform mole
are poorly understood. Except for the serial
assays of serum and urine human chorionic
gonadotrophin (hCG), there is no reliable pre-
dictor for the early detection of persistent
trophoblastic disease.
In this study, we assessed and compared tel-
omerase activity in normal placenta of different
gestational stages, hydatidiform mole, and
choriocarcinoma using the telomeric repeat
amplification protocol (TRAP) assay.5 The
significance of telomerase activity in the devel-
opment of normal placenta and pathogenesis
of gestational trophoblastic disease was investi-
gated. We are particularly interested in hyda-
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tidiform moles with the potential to produce
invasive or even metastatic disease. Such
malignant potential may be accompanied by
the immortalisation of the trophoblasts in the
hydatidiform mole, and this could involve acti-
vation of telomerase. The level of telomerase
activity was also correlated with clinical follow
up to see if high telomerase activity is
associated with the development of persistent
trophoblastic disease.
Methods
CLINICAL SAMPLES
Thirty five clinically and ultrasonographically
suspected cases of hydatidiform mole were
suction evacuated. Their gestational age
ranged from six to 22 weeks. Thirty placentas
of gestational age ranging from six to 20 weeks
and five term placentas were obtained after
induced abortion by suction evacuation or
normal delivery. Fresh chorionic villi and
molar vesicles were dissected, selected, snap
frozen in liquid nitrogen, and stored at -700C.
The rest of the tissue was fixed in formalin.
Thirty two of the 35 hydatidiform moles were
complete while the other three were partial.
Distinction between complete and partial
hydatidiform moles was by histological exam-
ination using well established diagnostic
criteria34 and in situ hybridisation. For confir-
mation of complete and partial moles by in situ
hybridrisation, biotinylated probes specific for
the pericentromeric regions of chromosomes
16 and X, as well as part of chromosome Y
(American Type Culture Collection, Rockville,
Maryland, USA), were used on formalin fixed
paraffin embedded tumour tissues.8 The clini-
cal records of patients with a diagnosis of
hydatidiform mole, including the postevacua-
tion hCG levels and administration of chemo-
therapy, were retrieved for assessment.
One case of choriocarcinoma, two choriocar-
cinoma cell lines (JAR and JEG3; American
Type Culture Collection), two cases of breast
carcinoma, and two cases of ovarian cystadeno-
carcinoma were also included in the study. The
HeLa cell line (cervical cancer) was used as
internal positive control for telomerase assay to
adjust for interassay variation.
EXTRACTION OF TELOMERASE
Telomerase was extracted from sections of
the frozen tissues or cell pellets according to
a previously published protocol.6 Briefly,
each frozen section or cell pellet was extracted
with 20 to 50 ,ul of ice cold lysis buffer.
The components of the lysis buffer were
10 mM Tris-HCl (pH 7.5), 1 mM MgCl2,
1 M EGTA, 0.1 mM phenylmethylsulphonyl
fluoride, 5 mM f3-mercaptoethanol, 0.5%
3- [(3-cholamidopropyl) dimethylamino]- 1-
propane sulphonate (Sigma), and 10% glycerol.
All precautions against RNase contamination
were observed. Frozen tissues or cell pellets
were homogenised in the cold lysis buffer with
disposable pestles and incubated on ice for 30
minutes. The homogenised lysate was centri-
fuged at 14 000 g for 30 minutes at 4°C and
aliquots of the supernatant were stored frozen
at -80°C until use. The telomerase activity in
the extract was then assessed by the telomeric
repeat amplification protocol (TRAP).`
TELOMERASE ASSAY-TELOMERIC REPEAT
AMPLIFICATION PROTOCOL (TRAP)
Telomerase activity was detected by its ability
to add repeats of TTAGGG to its substrate
(TS primer) which is an oligonucleotide
(5'AATCCGTCGAGCAGAGTT3'). This is a
two step reaction. The telomerase present in
the extracts would extend the TS primer to
generate an extended product. The telomerase
product generated was then amplified by
polymerase chain reaction (PCR) by including
the reverse primer (5'-CCCTTACCCTTAC-
C CTTA CCCTTAA-3') in the reaction.
Details of the TRAP assay have been
described previously.6 7The assay tubes were
prepared by sequestering 0.1 pg of CX primer
(5'-CCCTTACCCTTA-CCCTTACCCTT-
AA-3') under a wax barrier (Ampliwax; Perkin
Elmer Cetus). Each extract was assayed in 25,ul
of reaction mixture containing 20 mM Tris-
HCI (pH 8.0), 1.5 mM MgCl2, 60 mM KCI,
0.05% Tween 20, 1 mM EGTA, 50 jM deoxy-
nucleotide triphosphates, 0.1 jg of TS primer
(5'-AATCCGTCGAGCAGAGTT-3'), 0.5 jM
of T4 gene 32 protein (Boehringer Man-
nheim), 2 pCi of [c_-32P]dCTP (3000 Ci/mmol;
Amersham International), and 1.0 unit of Taq
DNA polymerase (Boehringer Mannheim). A
30 minute incubation period at room tempera-
ture was allowed for the telomerase mediated
extension of the TS primer. The reaction mix-
ture was then heated at 94°C for three minutes
and subjected to 31 PCR cycles (94°C for 30
seconds, 50°C for 30 seconds, and 72°C for 45
seconds). The PCR products were then
electrophoresed on a 15% polyacrylamide gel.
To ensure the specificity of the telomerase
assay, RNase pretreatment of the telomerase
extract (0.5 jg of RNase A for 30 minutes at
37°C) was always included for every sample
examined. Only RNase sensitive activities were
scored as telomerase activities.
The telomerase activity in each extract was
assayed at three concentrations (3 jg, 0.3 jg,
and 0.03 jg per reaction. The dilution allowed
a semiquantitative evaluation of telomerase
activity in the extract. In addition, the presence
of telomerase inhibitor in the extract might be
diluted, allowing telomerase activity to be
detected at a lower concentration of inhibitor.
The specificity of the TRAP assay was ensured
by the disappearance of the six base pairs (bp)
laddering signals after treatment with RNase.
For cases with negative telomerase activities,
the assay was repeated with the TRAPeze kit
(Oncor) with the inclusion of 36 bp internal
control in each reaction. This is to confirm that
the telomerase negative samples detected were
true negatives rather than resulting from the
presence ofPCR inhibitors in the TRAP assay.
The HeLa cell extract was also included in
each telomerase assay as a positive telomerase
control to adjust for interassay variation.
We examined the telomerase activity of
different stages of normal placenta, hydatidi-
form mole, choriocarcinoma sample and cell
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lines, as well as the breast and ovarian carcin
mas. Telomerase activity of the hydatidifor
mole was correlated with the clinical outcon
of the patients.
Results
Among the 35 hydatidiform moles studie
which included 32 complete moles and thr
partial moles, 27 regressed spontaneous
Eight of the patients had persistently rais
hCG level with a diagnosis of persiste
trophoblastic disease. Four of these eig
patients had documented metastases.
Figure 1 shows the telomerase activiti
detected in various trophoblastic tissues and
choriocarcinoma cell line (JAR) by the TRA
eze kit. There were apparent variations of tel
merase activities detected in different tropho
lastic tissues. Strong telomerase was detect4
in JAR cells. Comparatively weaker telomera
activity was detected in case 31, which was
first trimester placenta, and in case 29 whii
was a complete mole. No telomerase activi
was detected in case 30, which was also a cor
plete mole. There were variations in the level
telomerase detected among individual tr
phoblastic tissues. However, owing to t
semiquantitative nature of the telomerase ass
and other factors that might influence the le,
of telomerase activity detected, such
heterogeneity of trophoblastic tissues in t
specimens or the presence of a telomera
inhibitor, no direct comparison of telomera
activities among individual trophoblastic t
sues was made in this study.
The trophoblastic tissues were classified in
those with positive or negative telomera
activity and are summarised in table 1, togeth
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Figure 1 Telomerase activity in trophoblastic tissues. Telomerase activity was assayed at
three concentrations of the telomerase extract (3 ,ug, 0. 3 ug, and 0. 03 ,ug ofprotein per
reaction). RNase was included in each case to ensure the specificity of the telomerase assa
IC, internal control. 3AR was a choriocarcinoma cell line with clear telomerase activity
showed in all three dilutions of sample. Case 31 was afirst trimester placenta. Case 29 we
a complete mole with positive telomerase activity. Case 30 was another complete mole wit,
negative telomerase activity.
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Table 1 Telomerase activity in trophoblastic and other
tissues
Telomerase activity
Tissue Negative Positive
Placenta
Early (<20 weeks) (n=30) 19 11
Term (n=5) 4 1
Hydatidiform mole
Spontaneous regression 22 5
PTD with no metastasis (n=4) 1 3
PTD with metastasis (n=4) 1 3
Choriocarcinoma (n= 1) 1
Choriocarcinoma cell lines
JAR 1
JEG3 1
Ovarian carcinoma (n=2) 2
Breast carcinoma (n=2) 2
PTD, persistent trophoblastic disease.
tb- with their clinicopathological features. Positive
ed telomerase activity was defined as the detection
se of strong laddering signals in at least one of the
a three concentrations of extract (3 jg, 0.3 jg,
ch and 0.03 ,ug protein per reaction). Negative tel-
ity omerase activity was defined by the absence of
m- clear laddering signals in all the three concen-
of trations.
to- Telomerase activity was observed in 12 of 35
he cases of placentas (34.3%). It was detected at a
,ay higher frequency in early placentas (36.7 %; 11
vel positive cases out of 30) compared with term
as placentas (20%; one positive case out of five).
he However, the difference was not statistically
se significant (p < 0.05; Fisher exact test, two
ise tailed). In hydatidiform moles, telomerase
is- activity was detected in 1 1 of 35 cases (31.4%),
which was not significantly different from the
ito frequency detected in placental tissues
ise (34.3%). However, a higher frequency of
ler telomerase activation was detected in hydatidi-
form moles which developed persistent tro-
phoblastic disease (75%; three of four cases)
compared with those which regressed sponta-
neously (18.5%; five of 27 cases). The
difference was statistically significant
(p < 0.01; Fisher exact test, two tailed). The
frankly malignant tissues, which included one
choriocarcinoma tissue, two choriocarcinoma
cell lines, two ovarian carcinomas, and two
breast carcinomas, were all positive for telom-
erase activity.
Discussion
Telomere shortening may signal cessation of
cell division and trigger cell senescence. Main-
tenance of telomeric length is essential in
sustaining continuous cell proliferation. Telo-
merase activity is commonly activated to main-
tain the telomeric length in immortal cells.'
Telomerase activation has been demonstrated
in many types of human tumours, including
those developing in breast,5 nasopharynx,6
stomach,9 prostate,'0 urinary bladder," skin,'2
c cervix,7 and endometrium." These findings
suggest that telomerase activation is a crucial
step in human carcinogenesis. In tumours of
the breast, stomach, and urinary bladder, a
y. positive correlation between telomerase activity
and clinical stage or pathological grading of the
as tumours has been shown.5 9" Moreover, in-
creased telomerase activity has also been found
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to be associated with poor prognosis in gastric
carcinoma,' meningioma," hepatocellular
carcinoma,'" neuroblastoma,'6 and
leukaemia.'7 These findings suggest that high
levels of telomerase may impart a selective
growth advantage in tumour cells, probably
thorough stabilisation of telomeres. Lack of
correlation between telomerase activity and
clinicopathological features. has also been
reported,'8 19 which may be related to the diffi-
culties involved in accurate quantitation of tel-
omerase activity, as well as the purity of cancer
cells in the surgical specimens. Very few studies
have been reported on telomerase activation in
trophoblastic diseases.20 21
As with observations reported in other
malignant tumours, the choriocarcinoma sam-
ple and the two choriocarcinoma cell lines
showed strong telomerase activity. A few cases
of hydatidiform mole also showed positive tel-
omerase activity. In fact those cases which later
developed into persistent trophoblastic disease
and especially those that metastasised tended
to have a higher likelihood of telomerase
activation. Since telomerase activation plays an
important role in sustaining continuous cell
division in tumour growth,22 activation of
telomerase in hydatidiform mole may facilitate
the development of persistent disease. Further
study with a larger sample size is, however,
necessary to confirm this observation.
We detected telomerase activation in placen-
tal tissues, particularly those at an early
gestational stage. In another recent study, a
higher frequency oftelomerase activity was also
detected in early placentas compared with term
placentas.2' The mechanisms of telomerase
expression in the placenta are unclear but may
be related to proliferative activity in the early
placenta, which is important for invasion and
implantation. In endometrial lesions'3 23 and
human astrocytomas,2' it has already been
shown that telomerase expression is related to
proliferative activity. Wright et al reported that
telomerase activity was present in various fetal
tissues but not in the neonate.25 They specu-
lated that telomerase activity may be derived
from stem cells present in various tissues and is
required for organogenesis. Using proliferation
markers in placental tissues, we have previously
shown extensive proliferation in cytotropho-
blast which may function as stem cells in
placentas.26 27 Telomerase activity has also been
found in haematopoietic and epithelial
tissues.28 30 Our present findings support the
postulate that, besides tumours or immortal-
ised cell lines, normal somatic cells with stem
cell characteristics can express telomerase
activity. The telomerase activity observed in the
placenta may thus be derived from the stem cell
population of trophoblasts. The higher fre-
quency of telomerase activation in early
placentas may be related to their higher prolif-
eration rate compared with term placentas.26 27
Telomerase activity is downregulated during
differentiation of cells.3' 32 This may explain the
marked reduction in activity reported in late
placenta2' and may be related to the differentia-
tion of the placenta into mature villi which have
reduced proliferative activity.
The expression of telomerase activity in nor-
mal placentas may be related to other factors.
While peripheral blood lymphocytes are low in
telomerase activity, reactive lymphocytes in tis-
sues may express it.282 3 Hence lymphocytic
infiltration in the placental tissue is another
possible source of telomerase. The method
used in the extraction of telomerase involved
homogenisation of the placental tissue, which
prevents identification of the cellular origin of
the telomerase detected by the TRAP assay.
However, all the placental tissues were exam-
ined histologically before extraction for telom-
erase and we only included those that had
minimal contamination with infiltrating lym-
phocytes. The telomerase positive placental
tissues in our study did not contain a
significant population of lymphocytes on histo-
logical examination. On the other hand,
lymphocytic infiltration has been observed in
samples with negative telomerase activity, sug-
gesting that infiltrating lymphocytes are un-
likely to be the primary source of telomerase in
our study. Moreover, by special techniques of
isolation and preparation of trophoblasts, Kyo
et al have already confirmed that the trophob-
lastic cells are the major source of telomerase
activity in the placenta.20
It is interesting to note that similar telomer-
ase activity was found in both hydatidiform
moles and placentas in our study. In a previous
study on quantitative analysis of the prolifera-
tion index in spontaneous abortion, hydatidi-
form mole, and choriocarcinoma, we showed
that the choriocarcinoma group had a statisti-
cally higher proliferation index than spontane-
ous abortions and hydatidiform moles, while
there was no significant difference between
spontaneous abortions and hydatidiform
moles.' Apparently, hydatidiform mole, being
a chromosomally abnormal placenta in nature,
has a similar proliferative potential to normal
placenta of similar gestational age. We com-
pared the telomerase activation in hydatidiform
mole with the expression of proliferation mark-
ers such as Ki67, but no significant correlation
was observed. In another reported study using
a smaller number of cases of gestational
trophoblastic disease, hydatidiform mole as a
group was found to have higher telomerase
activity than normal villi.2' The significance of
this finding remains to be confirmed by a larger
sample study. Moreover, in complex tissues like
the placenta or hydatidiform mole, which are
composed of several cell types, accurate quan-
titation of telomerase activity is unlikely to be
straightforward.
In some cases the trophoblastic tissues were
negative for telomerase activity, including the
early placentas and hydatidiform moles which
developed metastases. We took the precaution of
ensuring that the lack of telomerase activity was
not due to the absence of hydatidiform mole in
the specimen tested, since all the samples were
checked histologically before extraction for
telomerase. Insensitivity of the telomerase assay
was also excluded by the presence of activity in
the control cell lines and the carcinoma samples.
The inclusion of internal control in the assay
also exclude the possibility that the absence of
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telomerase was caused by the presence of
inhibitor in the sample extract. The significance
of this finding is not fully understood at this
stage. It will be interesting to study telomeric
dynamics in those placental tissues with positive
telomerase activity compared with those with
negative activity. Nonetheless, absence of telom-
erase activity has been found in some human
cancers, including retinoblastoma and breast
cancers.22 11 15 Telomere maintenance in these
immortal tumour cells may involve telomerase
independent mechanisms.363"
CONCLUSIONS
Our results show that telomerase activity was
present in choriocarcinoma as well as in early
placentas and hydatidiform moles. The similar
pattern of telomerase expression in hydatidi-
form moles and placentas of early gestational
age may reflect the comparable nature of the
hydatidiform mole and the abnormal concep-
tus. On the other hand, hydatidiform moles
which progressed to gestational trophoblastic
disease tended to express telomerase activity
more often than those which regressed sponta-
neously. A larger scale study is warrant to
evaluate the prognostic significance of telomer-
ase in predicting the clinical behaviour of
hydatidiform mole.
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